Shanghai Tianma Am-oled Co., Ltd.

Huawei Technologies Co., Limited

Other

General Electric Company

Hon Hai Precision Industry Co., Ltd.

Marvellworld Trade Ltd.

Mcneil-ppc, Inc.

Mochida Pharmaceutical Co., Ltd.

Fudan University

Ambit Microsystems (shanghai) Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Bilibili Technology Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

China Unionpay Co., Ltd.

Wangsu Science & Technology Co., Ltd.

Jie Li

Jian Li

Shuhui Chen

Wenyuan Qian

Chundao Yang

Xiangcheng Wang

Yuji Hamada

Wentao Wu

Lixin Zhao

Jianfei Wang

Zhen Gong

Zhixiang Li

Jikui Sun

Wenqiang Li

Wei He

Lei Zhang

Chen Liu

Zhengxia Chen

Hongyang Ren

Haizhong Tan

Jian Wang

Jinghua Niu

Yi Zhang

Fei Wang

Haiying He

Weikang Tao

Yu Ying Wang

Piaoyang Sun

Yan Wu

Ying Liu

Tsutomu Satoh

Yonggang Wang

Lianshan Zhang

Fener Chen

Tao Feng

Qing Zhu

Qiyi Luo

Scott Martell Boyette

Zhigan Jiang

Honglin Nie

Meibi Dai

Zhifei Fu

Meng-Wei Kuo

Yan Xi Jin

Miaorong Luo

Zhen Yan

Wenjie Wu

Zhengwei Li

Xungui He

Yikai Wang

Yanling Wang

Biao Yan

Huihui Ma

Minxi Fang

Guangwen Yang

Ze Xu

Chuanjun Liu

Jirang Zhu

Qingzhong Cheng

Mingyong Yuan

Zhimin Huang

Simin Chen

Zhaodi Fan

Yanming Yang

Jian Qin

Hai Zhao

Yan Fang

Rong Hong Xu

Xiaoping Zheng

Kuo-Wei Hung

Zaifang Ren

Daozhi Liu

Yangyang Xu

Wenyuan Zhu

Pingping Wang

Fangjun Xiong

Guanghai Xu

Chao Xie

Jinguang Lin

Chunbo Sha

Hideharu Uchida

Fenglai Sun

Linlin Chen

Qiu Li

Yanbin Gao

Hui He

Juan Jiang

Randy Koval

Dipanjan Basu

Rongxin Huang

Deyao Li

Pingping Zhan

Lingjun Xu

Qiuqin He

Wenxue Chen

Xiayun Huang

Weiwen Sheng

Fengliang Zhao

Yan-bin Gao

Systems, apparatuses and methods may provide for memory cell technology comprising a control gate, a conductive channel, and a charge storage structure coupled to the control gate and the conductive channel, wherein the charge storage structure includes a polysilicon layer and a metal layer. In one example, the metal layer includes titanium nitride or other high effective work function metal.

Metal hybrid charge storage structure for memory

Provided are a class of multi-targeted inhibitors of IRAK4 and BTK, and the use thereof in preparing a drug for treating IRAK4- and BTK-related diseases. The present invention specifically relates to the compounds represented by formula (II), isomers thereof or pharmaceutically acceptable salts thereof.

Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.

Crystal form of Wee1 inhibitor compound and use thereof

The present invention provides, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the production of formula (I).

Method for producing heterocyclidene acetamide derivative

This application provides a data storage method which is applied to a data storage device and includes: acquiring a first user identification and first user data of a first user; determining, from at least two preset distributed hosts in different areas, a first identification distributed host corresponding to the first user identification and a first data distributed host corresponding to the first user data; sending the first user identification to the first identification distributed host, so that the first identification distributed host stores the first user identification, and generates and stores a first identity identification corresponding to the first user identification; receiving the first identity identification; and sending the first identity identification and the first user data to the first data distributed host, so that the first data distributed host stores them in an associated manner.

Data storage method, apparatus, device and storage medium using distributed hosts for user identifications

A method is provided. The method includes: obtaining a picture to be processed, where the picture to be processed includes a plurality of pixels, and the plurality of pixels comprise first pixels for forming an image and second pixels for forming an image background; rotating the picture to be processed, where for each rotation angle, an intermediate picture is obtained; selecting at least two pictures from the picture to be processed and several intermediate pictures for calculating an area of a bounding box surrounding the image respectively; and removing second pixels outside the bounding box in a picture with the smallest area of bounding box to obtain a processed picture.

Rotating and cropping images for various forms of media including animation, comics, film, or television

A method and a system of automatically generating animations imports Json data exported from a Spine tool into a Unity3d tool, parses the Json data into an animation data format by the Unity3d tool, obtains key frame information from the animation data format and stores the key frame information as an animation file of the Unity3d tool, and runs the animation file to play an animation. The present invention does not need to remake the Spine key frame in the Unity3d tool, and the key frame can be automatically generated. The animation key frame effects of the Spine tool can be reproduced, such as displacement, zooming, rotation, and color change, and the animation made by the artist in the Spine tool can be accurately restored, which reduces repetitive work and greatly improves the efficiency of game development.

Method and system of automatic animation generation

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.

Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases

Disclosed are a thieno[2,3-c]pyridazin-4(1H)-one derivative as an ACC1 or ACC2 inhibitor and an application thereof in preparing a drug as an ACC1 or ACC2 inhibitor. In particular, disclosed is a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof. 

Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof

Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Macrocyclic compound serving as Wee1 inhibitor and applications thereof

A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. 

Pyrazolopyrimidine derivative and use thereof

Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof. 

Isothiazolo[5,4-D]pyrimidine compound as IRAK4 inhibitor

Disclosed are a compound as an ATR inhibitor and an application in preparing a drug as an ATR inhibitor. In particular, disclosed is a compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof. 

ATR inhibitor and application thereof

The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. 

Heterocyclic compound as CSF-1R inhibitor and use thereof

Growing community of inventors

Shanghai, China

Jie Li